Literature DB >> 7860051

Breast cancer heterogeneity: evaluation of clonality in primary and metastatic lesions.

W F Symmans1, J Liu, D M Knowles, G Inghirami.   

Abstract

Breast cancers often contain different clones of tumor cells. Attention to the cellular properties of breast cancer metastases may identify characteristics in primary tumors that are associated with metastasis. Such characteristics could include DNA content, cell proliferation, abnormal oncogene expression, or relative cell population (clonal dominance). We examined DNA ploidy (image analysis), proliferation index (proliferating cell nuclear antigen-1 immunostaining), and expression of Her-2/neu oncoprotein in 17 invasive breast cancer samples (36 primary tumor samples) and 82 corresponding regional metastases. In all samples the primary tumor was multiclonal (usually biclonal) by DNA ploidy analysis. In approximately 90% of metastatic DNA clones (30 of 34) the corresponding clone was identified in a primary tumor sample representing 25% or more of the tumor cell population (significant clone). A majority DNA clone (> or = of tumor cell population) existed in 60% (21 of 36) of primary tumor samples and in 70% (60 of 82) of metastases (30% diploid v 70% nondiploid in both groups). In approximately 50% of metastases (37 of 82) an unexpected majority clone was identified (not a majority in any primary tumor sample) and the ratio of diploid to nondiploid clones also was 30% to 70%. However, in 80% of majority metastatic clones (46 of 60) that clone was a significant primary tumor clone. Proliferation index was quite variable in primary tumor samples and in corresponding metastases. Overexpression of Her-2/neu oncoprotein in the primary tumor of seven of 10 patients also was identified in all corresponding metastases in five of seven patients and in some metastases in two of seven patients. The metastases in three Her-2/neu-negative patients were all negative. We conclude that (1) DNA clones are stable after metastasis, (2) clonal majorities in metastases reflect clones identified in primary tumors, (3) different metastatic clones from an individual tumor can establish clonal majorities, (4) neither diploid nor aneuploid cells have a metastatic advantage in breast cancer, (5) proliferation indices are heterogeneous, and (6) overexpression of Her-2/neu is usually consistent between primary tumors and corresponding metastases.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7860051     DOI: 10.1016/0046-8177(95)90039-x

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  23 in total

Review 1.  The clonal origin and clonal evolution of epithelial tumours.

Authors:  S B Garcia; M Novelli; N A Wright
Journal:  Int J Exp Pathol       Date:  2000-04       Impact factor: 1.925

2.  Expression of molecular biomarkers in primary breast tumors implanted into a surrogate host: increased levels of cyclins correlate with tumor progression.

Authors:  G Wani; I Noyes; G E Milo; S M D'Ambrosio
Journal:  Mol Med       Date:  1997-04       Impact factor: 6.354

3.  Prognostic gene expression signatures can be measured in tissues collected in RNAlater preservative.

Authors:  Dondapati Chowdary; Jessica Lathrop; Joanne Skelton; Kathleen Curtin; Thomas Briggs; Yi Zhang; Jack Yu; Yixin Wang; Abhijit Mazumder
Journal:  J Mol Diagn       Date:  2006-02       Impact factor: 5.568

4.  Beyond comparing means: the usefulness of analyzing interindividual variation in gene expression for identifying genes associated with cancer development.

Authors:  Ivan P Gorlov; Jinyoung Byun; Hongya Zhao; Christopher J Logothetis; Olga Y Gorlova
Journal:  J Bioinform Comput Biol       Date:  2012-04       Impact factor: 1.122

5.  Selection, establishment and characterization of cell lines derived from a chemically-induced rat mammary heterogeneous tumor, by flow cytometry, transmission electron microscopy, and immunohistochemistry.

Authors:  L Teodori; F Tagliaferri; F Stipa; M G Valente; D Coletti; A Manganelli; M Guglielmi; L S D'Angelo; H Schäfer; W Göhde
Journal:  In Vitro Cell Dev Biol Anim       Date:  2000-03       Impact factor: 2.416

6.  Tissue microarrays for rapid linking of molecular changes to clinical endpoints.

Authors:  J Torhorst; C Bucher; J Kononen; P Haas; M Zuber; O R Köchli; F Mross; H Dieterich; H Moch; M Mihatsch; O P Kallioniemi; G Sauter
Journal:  Am J Pathol       Date:  2001-12       Impact factor: 4.307

7.  Genetic heterogeneity of primary and metastatic breast carcinoma defined by fluorescence in situ hybridization.

Authors:  J F Simpson; D E Quan; J P Ho; M L Slovak
Journal:  Am J Pathol       Date:  1996-09       Impact factor: 4.307

8.  Deformable registration for quantifying longitudinal tumor changes during neoadjuvant chemotherapy.

Authors:  Yangming Ou; Susan P Weinstein; Emily F Conant; Sarah Englander; Xiao Da; Bilwaj Gaonkar; Meng-Kang Hsieh; Mark Rosen; Angela DeMichele; Christos Davatzikos; Despina Kontos
Journal:  Magn Reson Med       Date:  2014-07-15       Impact factor: 4.668

9.  Gene expression profiles identify inflammatory signatures in dendritic cells.

Authors:  Anna Torri; Ottavio Beretta; Anna Ranghetti; Francesca Granucci; Paola Ricciardi-Castagnoli; Maria Foti
Journal:  PLoS One       Date:  2010-02-24       Impact factor: 3.240

10.  Concordance of the HER2 protein and gene status between primary and corresponding lymph node metastatic sites of extramammary Paget disease.

Authors:  Ryota Tanaka; Yuko Sasajima; Hitoshi Tsuda; Kenjiro Namikawa; Akira Takahashi; Arata Tsutsumida; Yasuhiro Fujisawa; Manabu Fujimoto; Naoya Yamazaki
Journal:  Clin Exp Metastasis       Date:  2016-06-11       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.